Su, Yung-Yeh
Chiu, Yen-Feng
Li, Chung-Pin
Yang, Shih-Hung
Lin, Johnson
Lin, Shyh-Jer
Chang, Ping-Ying
Chiang, Nai-Jung
Shan, Yan-Shen http://orcid.org/0000-0002-2457-5189
Ch’ang, Hui-Ju http://orcid.org/0000-0002-3706-1769
Chen, Li-Tzong http://orcid.org/0000-0003-3250-7167
Funding for this research was provided by:
National Health Research Institutes (CA-101~108-PP 25)
Article History
Received: 13 July 2021
Revised: 1 November 2021
Accepted: 22 November 2021
First Online: 17 December 2021
Competing interests
: L-TC reports research funding from Novartis, Merck, Serono, TTY, Polaris, SyncorePharm, Pfizer, BMS; honoraria from ONO, Eli Lilly, MSD, PharmaEngine, TTY, SyncorePharm, Novartis, Astra Zeneca, Ipsen; patents and royalties from ENO-1mAb/HuniLife; membership on Board of Directors of ScinoPharm, Taiwan, Ltd. and on Scientific Advisory Committee of PharmaEngine. All the remaining authors declare no competing interests.
: The study protocol and informed consent forms were approved by the Research Ethics Committee, National Health Research Institutes, Taiwan (reference number: EC1010805) and the Institutional Review Board of each participating hospital. All subjects provided written informed consent prior to participating in the study. The study was conducted in accordance with the Declaration of Helsinki.